IP Library Patent Application 17988857
Patent Application
App. No. 17/988,857

Liposomes Useful for Drug Delivery

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/988,857
Abstract

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Claims (13)

1 - 20 . (canceled)

21 . A pharmaceutical composition comprising irinotecan liposomes encapsulating the irinotecan and a polyphosphate having 13-18 phosphate units per polyphosphate molecule, wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.7.

22 . The composition of claim 21 , comprising a lecithin and cholesterol.

23 . The composition of claim 22 , wherein the lecithin:cholesterol molar ratio is 3:2.

24 . The composition of claim 21 , comprising DSPC and cholesterol in a 3:2 molar ratio.

25 . The composition of claim 21 , comprising DSPC, cholesterol, and an amphipathic polymer comprising a polyethylene glycol-lipid.

26 . The composition of claim 25 , wherein the polyethylene glycol-lipid is a polyethylene glycol phosphatidylethanolamine.

27 . The composition of claim 26 , wherein the polyethylene glycol phosphatidylethanolamine has a poly(ethylene glycol) moiety having a molecular weight ranging from about 250 to about 20,000.

28 . The composition of claim 21 , comprising DSPC, cholesterol, and N-(methoxy-poly(ethylene glycol)-oxycarbonyl)-di stearoylphosphatidylethanolamine, in a molar ratio of 3:2:0.015.

29 . The composition of claim 21 , comprising DSPC, cholesterol, and methoxy-PEG(2000)-DSPE, in a molar ratio of 3:2:0.015.

30 . The composition of claim 21 , comprising one or more phospholipids, and wherein the liposomes encapsulate irinotecan and a polyphosphate having 13-18 phosphate units per polyphosphate molecule, and the ratio of grams of irinotecan to moles of total phospholipids is (134.4±9.3):1.

31 . The composition of claim 21 , comprising one or more phospholipids, and wherein the liposomes encapsulate irinotecan and a polyphosphate having 13-18 phosphate units per polyphosphate molecule, and the ratio of grams of irinotecan to moles of total phospholipids is (162.4±4.0):1.

32 . The composition of claim 21 , wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.3.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE 1ST ASSIGNOR FROM KEE HONG TO KEELUNG HONG PREVIOUSLY RECORDED ON REEL 062569 FRAME 0179. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 3, 2023
From: HONG, KEELUNG; DRUMMOND, DARYL C.; KIRPOTIN, DMITRI
To: HERMES BIOSCIENCES, INC.
Reel/Frame 062649/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2023
From: HONG, KEE; DRUMMOND, DARYL C.; KIRPOTIN, DMITRI
To: HERMES BIOSCIENCES, INC.
Reel/Frame 062569/0179 →
MERGER Recorded Feb 2, 2023
From: HERMES BIOSCIENCES, INC.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 062569/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2023
From: MERRIMACK PHARMACEUTICALS, INC.
To: IPSEN BIOPHARM LTD.
Reel/Frame 062569/0217 →